Plasmodium parasite

The term **"Plasmodium parasite"** refers collectively to unicellular eukaryotic protozoa in the genus *Plasmodium*, which are obligate intracellular parasites responsible for malaria in humans and other animals. Over two hundred species have been described, with several infecting humans—most notably *Plasmodium falciparum* (the deadliest), *P. vivax*, *P. ovale*, and *P. malariae*. These parasites have complex life cycles involving both vertebrate hosts (where they infect liver cells then red blood cells) and insect vectors (*Anopheles* mosquitoes). Within host erythrocytes they digest hemoglobin—producing hemozoin pigment—and evade immune responses through variant surface proteins such as PIRs, RIFINs, or STEVORs depending on species.[1][4][7] From a therapeutic perspective, "Plasmodium parasite" is not itself considered a single molecular target but rather an organism containing numerous potential drug targets—including enzymes like kinases,[2] chaperonins,[5] metabolic pathways unique to apicomplexans,[1] or processes like hemoglobin digestion.[8] Drug discovery efforts focus on identifying essential molecules within these parasites that can be selectively inhibited without harming human host cells. Because "Plasmodium parasite" does not refer to one defined molecule/receptor/protein but rather an entire genus of pathogens comprising hundreds of genes/proteins/pathways that may serve as individual therapeutic targets,[3] it is **not appropriate** as a canonical therapeutic target name under standard conventions—it is too broad and non-specific. > The genus *Plasmodium* consists of all eukaryotes in the phylum Apicomplexa that both undergo the asexual replication process inside host red blood cells and produce crystalline pigment hemozoin from digesting hemoglobin... Species contain features common to other eukaryotes plus unique organelles involved in invasion/modification of host cells... Both mitochondrion and apicoplast play key roles in metabolism...[1] > New drugs targeting multiple *Plasmodium* life stages are needed... clemastine binds/destabilizes essential chaperonin TRiC/CCT...[5] > Identification/validation of new drug targets within *Plasmodium* is crucial for novel antimalarials capable against resistant populations...[3] **Summary:** “Plasmodium parasite” refers broadly to pathogenic protozoa causing malaria—not one discrete molecular entity suitable for structured pharmacological data extraction about receptors/enzymes/etc.; instead it encompasses many possible validated or investigational molecular targets within its genome/proteome/metabolome.[1][2][3]

Other names

PlasmodiumMalaria parasitePlasmodium species (e.g., Plasmodium falciparum, Plasmodium vivax)

Varies by drug; examples include: - Inhibition of heme detoxification pathway (chloroquine, quinolines)[8] - Disruption of protein folding machinery (clemastine targets TRiC/CCT chaperonin)[5] - Inhibition of kinases essential for survival and replication[2]